Recombitant α2b-Interferon in the Management of Myelodysplastic Syndromes
Interferon treatment is effective in hairy cell and chronic granulocytic leukaemia although the exact mechanism of its antileukaemic action is uncertain. Since its cytoreductive, differentiation and immunoregulatory effects are potentially useful in myelodysplastic syndromes (MDS), a therapeutic study was undertaken on this condition.
KeywordsMyelodysplastic Syndrome Cytosine Arabinoside Hairy Cell Immunoregulatory Effect Queen Elizabeth Hospital
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bennett TM, Catovsky D, Daniel MT et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic states — a scoring system with prognostic significance. Br J Haematol 59: 425–433PubMedCrossRefGoogle Scholar
Herberman RB, Ortaloo JR, Mantovani A et al. (1982) Effect of human recombinant interferon on cytotoxic activity of natural killer ( NK) cells and monocytes. Cell Immunol 67: 160–167Google Scholar
Grant S, Bhalla K, Weinstein IB et al. (1982) Differential effect of recombinant human leucocyte interferon on human leukaemic and normal myeloid progenitor cells. Biochem Biophys Res Commun 108: 1048–1055PubMedCrossRefGoogle Scholar
Quesada JR, Reuben J, Manning JT, Harsh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukaemia. N Engl J Med 310: 15–18PubMedCrossRefGoogle Scholar
© Springer-Verlag Berlin Heidelberg 1992